Immune Design (IMDZ) Announces Data Update for Lead Immunotherapy Programs – StreetInsider.com
|
Immune Design (IMDZ) Announces Data Update for Lead Immunotherapy Programs
StreetInsider.com Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced updated data from two separate trials evaluating its lead product candidates, CMB305 and G100. CMB305 is a novel prime-boost … |
